Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM98RW0)

Drug Name

Cirmtuzumab Drug Info

Synonyms

UC-961

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Mantle cell lymphoma	2A85.5	Phase 1/2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neurotrophic tyrosine kinase ROR1 (ROR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zilovertamab vedotin	DM1MZAQ	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[3]
VLS-101	DMLT94F	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
Zilovertamab	DMMEJ6K	Mantle cell lymphoma	2A85.5	Phase 2	[5]
NBE-002	DMTAODR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
ROR1R-CAR-T Cell	DMIAK9P	leukaemia	2A60-2B33	Phase 1	[7]
ROR1 CAR-specific Autologous T-Lymphocytes	DM5EUIY	Acute lymphoblastic leukaemia	2A85	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neurotrophic tyrosine kinase ROR1 (ROR1)	TTDEJAU	ROR1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04501939) Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377.
4	Clinical pipeline report, company report or official report of VelosBio.
5	The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.
6	Clinical pipeline report, company report or official report of NBE-Therapeutics.
7	ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
8	ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies